Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business
Shots:
- Pfizer plans to combine its off-patent drug business with Mylan with the formation of a new entity for the generic business. Post completion of the deal- Mylan will hold 40% of the shares and remaining will belong to Pfizer
- The merger will boost the sales of therapies which slowed due to loss of patent protection and began facing lower-priced competition. Additionally- Pfizer would receive $12B in proceeds from a new sale of debt
- Pfizer’s off-patent drug includes Lipitor cholesterol pills and Viagra (the male impotence drug)- Mylan’s EpiPen is an auto-injector for injecting a measured dose of epinephrine used to treat anaphylaxis
Click here to read full press release/ article | Ref: The Wall Street Journal | Image: Emaze
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com